Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing existing literature without systematic search methodology
PubMed 32077010 · doi:10.1007/5584_2020_496
What was done
Narrative review of human literature examining how endogenous GLP-1 and GLP-1 receptor agonists affect gastric motor function, focusing on gastric emptying measured by scintigraphy and acetaminophen absorption tests in patients with type 2 diabetes mellitus and obesity.
What was found
No numerical values or effect sizes are reported in the abstract. Qualitatively, GLP-1 infusion and GLP-1 receptor agonists retard gastric emptying and increase fasting and postprandial gastric volumes, leading to reduced postprandial glycemia. The effect on gastric emptying attenuates with long-acting preparations or chronic short-acting use due to tachyphylaxis, and dual GLP-1/GIP agonists did not retard gastric emptying in available reports.
Why it matters
Clarifies that the glycemic benefits of GLP-1 receptor agonists depend partly on decelerated gastric emptying, while highlighting tachyphylaxis as a major modifier of this effect during prolonged or long-acting therapy.
Limits
Narrative review format with no systematic search methodology, meta-analytic pooling, or risk of bias assessment. The abstract provides no quantitative data, effect estimates, or participant counts.
Cited by
- supports Endogenous human GLP-1 is cleared rapidly, whereas engineered pharmaceutical GLP-1 agonists have a half-life of 5 to 7 days.